Elysium Therapeutics Webcast to Address Opioid Crisis Solutions
Elysium Therapeutics, a pioneering biopharmaceutical company focused on creating life-saving treatments for opioid overdoses, recently announced an upcoming investor webcast. This event will shine a light on their Synthetic Opioid Overdose Prevention and Reversal (SOOPR™) Program. The focus will be on the crucial need to tackle the challenge of fentanyl rebound—an issue that has become increasingly concerning in the context of the opioid overdose epidemic.
Opioid overdoses, particularly those involving synthetic variants like fentanyl, pose significant risks to individuals. During the webcast, Co-Founder and CEO of Elysium Therapeutics, Greg Sturmer, expressed urgency in addressing the consequences of fentanyl rebound, commonly referred to as re-narcotization. This phenomenon can lead to severe respiratory distress and, in extreme cases, death.
"Currently available treatments, such as Narcan® and Opvee®, have shown shortcomings when it comes to reversing overdoses caused specifically by synthetic opioids like fentanyl,” Sturmer explained. "There is an immense need for innovative solutions that not only reverse the effects of these drugs but also prevent the risks associated with fentanyl rebound.”
The SOOPR™ Program aims to offer a first-of-its-kind therapy designed for quicker onset and longer-lasting effects in treating opioid overdose situations. This innovative approach represents a substantial advancement in managing the complexities of synthetic opioid overdoses.
Details of the Webcast
During the webcast, Sturmer will be joined by Chief Scientific Officer Tom Jenkins, Ph.D. Together, they will discuss the critical importance of new rescue medications that can help reduce the fatalities linked to synthetic opioids, particularly focusing on the rebound phenomenon associated with fentanyl usage.
Webcast Details:
Event Overview
The title of the event will be "Innovating Solutions for Fentanyl Rebound - Elysium Therapeutics & SOOPR - Investor Webcast". This informative session aims to engage investors and provide insight into the company’s strategic direction in combatting the opioid crisis.
Date and Time
The investor webcast will take place on a Monday afternoon at 2:00 PM ET. Participants are encouraged to register ahead of time to secure their access.
Joining the Webcast
To join the webinar, interested parties can access the Zoom link provided for registration. It’s advisable to have the meeting ID and access codes handy for a seamless entry into the session.
About SOOPR™
The SOOPR (Synthetic Opioid Overdose Prevention and Resolution) is crafted as a rapid-onset, long-acting rescue tool, specifically aimed at countering the effects of synthetic opioid overdoses. Utilizing proprietary formulations, SOOPR seeks to provide timely interventions that effectively restore normal breathing and maintain opioid blockade for an extended period—spanning up to 24 hours. This mechanism aims to counteract the issues associated with the fast-acting nature of synthetic opioids.
About Elysium Therapeutics
Elysium Therapeutics is dedicated to developing innovative treatments that address the severe limitations of existing opioid rescue medications. With a commitment to improving safety standards in the opioid industry, Elysium aims to introduce first- and best-in-class solutions that can effectively reduce the impact of opioid-use disorder and the risks associated with overdose. Their lead technology, SOOPR™, is a testament to their mission in providing effective alternatives in critical situations.
Frequently Asked Questions
What is the focus of the Elysium Therapeutics webcast?
The webcast will focus on the SOOPR™ Program and the urgent issue of fentanyl rebound in the opioid crisis.
Who will be speaking during the webcast?
CEO Greg Sturmer and CSO Tom Jenkins, Ph.D., will lead the discussion during the webcast.
When is the investor webcast taking place?
The investor webcast is scheduled for an afternoon on a Monday at 2:00 PM ET.
What does SOOPR™ stand for?
SOOPR™ stands for Synthetic Opioid Overdose Prevention and Reversal.
How does SOOPR™ differ from current overdose medications?
SOOPR™ is designed to offer a rapid-onset and long-acting solution tailored specifically for synthetic opioid overdoses, addressing weaknesses found in existing treatments.
